Search - tctmd.com

Displaying 1 - 20 of 69

Sort: Relevancy | Date

Presentation TCT 2025

TCT 69: Optimal P2Y12 inhibitor strategy after acute coronary syndrome: a network meta-analysis of randomised controlled trials

Presenter: Yousif Ahmad

October 28, 2025

Presentation TCT 2025

TCT 995: Less Is More? P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy following PCI In Acute Coronary Syndrome: A Meta-Analysis of Reconstructed Time-to-Event Data

Presenter: Paulo Roberto Tartuce Filho

October 27, 2025

Presentation TCT 2025

TCT 1677: Managing Acute Coronary Syndrome in the Context of High Thrombotic Burden and P2Y12 Inhibitor Resistance

Presenter: Amitoj Singh

October 27, 2025

Presentation TCT 2025

TCT 55: A Meta-Analysis on Safety and Efficacy of P2Y12 Inhibitor Monotherapy versus Aspirin Monotherapy After 12 Months of DAPT in Patients Post Percutaneous Coronary Intervention

Presenter: Asna Aafreen

October 26, 2025

Presentation TCT 2025

TCT 52: Differential Prognostic Impact of Potent P2Y12 inhibitors in Patients with Acute Myocardial Infarction According to Bleeding Risk

Presenter: Seung Hun Lee

October 26, 2025

Presentation TCT 2024

Debate Pro: Always

Presenter: Marco Valgimigli

October 30, 2024

Presentation TCT 2024

Debate Con: Never

Presenter: Dominick Angiolillo

October 30, 2024

Presentation TCT 2024

TCT 227: Timing and Indications for Cangrelor Use and Transition Modalities to Oral P2Y12 Inhibitors in Patients Undergoing PCI: Insights From the SMILE Study

Presenter: Angelo Oliva

October 27, 2024

Presentation TCT 2023

TCT 657: Aspirin versus P2Y12 inhibitor as a combination therapy with direct oral anticoagulant after coronary stent implantation in patients with atrial fibrillation (AF).

Presenter: Hyunki LEE

October 25, 2023

Presentation TCT 2023

TCT 354: The clinical impact of Dual Antiplatelet Therapy score combined with P2Y12 reactivity unit on East Asian patients who received drug eluting stent implantation; PTRG-DES Consortium

Presenter: Seong Huan Choi

October 25, 2023

Presentation TCT 2023

TCT 37: The association of CHADS-P2A2RC risk score with clinical outcomes in patients taking P2Y12 inhibitor monotherapy after 3 months of dual antiplatelet therapy following percutaneous coronary intervention

Presenter: Ji-Yeon Kim

October 25, 2023

Presentation TCT 2023

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

Presenter: Michael Savage

October 25, 2023

Presentation TCT 2023

TCT 557: Real World Adherence to High Potency P2Y12 Inhibitor Therapy in Patients Treated for ST Elevation Myocardial Infarction

Presenter: Wadie David

October 24, 2023

Presentation TCT 2023

TCT 44: P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study

Presenter: Seung-Yul Lee

October 24, 2023

Presentation TCT 2022

TCT 12: Early Predictors of Left Main and Three-Vessel Coronary Artery Disease in Patients with Non-ST Elevation Acute Coronary Syndrome and Implications for Upstream P2Y12 Inhibitor Administration

Presenter: Rayan Jo Rachwan

September 18, 2022

Presentation TCT 2022

P2Y12 Inhibitors in ACS: Which Agent in Which Patient and When?

Presenter: Davide Capodanno

September 18, 2022

Presentation Cardiovascular Interventions 2020

Anatomic Complexity and Choice of P2Y12: Cases for the Panel

Presenter: Duane Pinto

November 13, 2020

Presentation TCT 2020

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

Presenter: Jennifer Rymer

October 14, 2020

Presentation TCT 2020

TCT 062: Short Term Dual Anti-Platelet Therapy Followed by P2Y12 Monotherapy After Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Control Trials

Presenter: Mohammad Saud Khan

October 14, 2020

Presentation JIM 2020

Clinical Crossroads On Optimal Antithrombotic Therapy In Patients Treated With Pci Intravenous Antiplatelet Therapy In High Risk Acs

Presenter: Dominick Angiolillo

February 13, 2020

Advertisement

TCT 69: Optimal P2Y12 inhibitor strategy after acute coronary syndrome: a network meta-analysis of randomised controlled trials

TCT 995: Less Is More? P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy following PCI In Acute Coronary Syndrome: A Meta-Analysis of Reconstructed Time-to-Event Data

TCT 1677: Managing Acute Coronary Syndrome in the Context of High Thrombotic Burden and P2Y12 Inhibitor Resistance

TCT 55: A Meta-Analysis on Safety and Efficacy of P2Y12 Inhibitor Monotherapy versus Aspirin Monotherapy After 12 Months of DAPT in Patients Post Percutaneous Coronary Intervention

TCT 52: Differential Prognostic Impact of Potent P2Y12 inhibitors in Patients with Acute Myocardial Infarction According to Bleeding Risk

Debate Pro: Always

Debate Con: Never

TCT 227: Timing and Indications for Cangrelor Use and Transition Modalities to Oral P2Y12 Inhibitors in Patients Undergoing PCI: Insights From the SMILE Study

TCT 657: Aspirin versus P2Y12 inhibitor as a combination therapy with direct oral anticoagulant after coronary stent implantation in patients with atrial fibrillation (AF).

TCT 354: The clinical impact of Dual Antiplatelet Therapy score combined with P2Y12 reactivity unit on East Asian patients who received drug eluting stent implantation; PTRG-DES Consortium

TCT 37: The association of CHADS-P2A2RC risk score with clinical outcomes in patients taking P2Y12 inhibitor monotherapy after 3 months of dual antiplatelet therapy following percutaneous coronary intervention

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

TCT 557: Real World Adherence to High Potency P2Y12 Inhibitor Therapy in Patients Treated for ST Elevation Myocardial Infarction

TCT 44: P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study

TCT 12: Early Predictors of Left Main and Three-Vessel Coronary Artery Disease in Patients with Non-ST Elevation Acute Coronary Syndrome and Implications for Upstream P2Y12 Inhibitor Administration

P2Y12 Inhibitors in ACS: Which Agent in Which Patient and When?

Anatomic Complexity and Choice of P2Y12: Cases for the Panel

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

TCT 062: Short Term Dual Anti-Platelet Therapy Followed by P2Y12 Monotherapy After Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Control Trials

Clinical Crossroads On Optimal Antithrombotic Therapy In Patients Treated With Pci Intravenous Antiplatelet Therapy In High Risk Acs

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content